The downregulation of MAPK and PI3K/AKT signaling within tumor regions aligns with reduced proliferative and survival signaling, pathways that are frequently activated in PDAC and associated with aggressive disease biology and therapeutic resistance [32,33]. Here, AKT1 is linked to neoplasm.